Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Int J Mol Med. 2011 Oct;28(4):653-8. doi: 10.3892/ijmm.2011.747. Epub 2011 Jul 12.
We have previously reported that thrombin stimulates synthesis of interleukin-6 (IL-6), a potent bone resorptive agent, in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the mechanism of thrombin in the thrombin-stimulated IL-6 synthesis and the involvement of Rho-kinase in MC3T3-E1 cells. Thrombin time-dependently induced the phosphorylation of p44/p42 mitogen-activated protein (MAP) kinase, p38 MAP kinase, stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and myosin phosphatase targeting subunit-1 (MYPT-1), a Rho-kinase substrate. While SP600125, an inhibitor of SAPK/JNK, failed to reduce IL-6 synthesis, PD98059, a specific inhibitor of MEK, and SB203580 and BIRB0796, potent inhibitors of p38 MAP kinase, suppressed the IL-6 synthesis induced by thrombin. Y27632, a specific Rho-kinase inhibitor, significantly reduced thrombin-stimulated IL-6 synthesis as well as the MYPT-1 phosphorylation. Fasudil, another inhibitor of Rho-kinase, suppressed thrombin-stimulated IL-6 synthesis. Y27632 and fasudil failed to affect thrombin-induced phosphorylation of p44/p42 MAP kinase. Y27632 as well as fasudil attenuated thrombin-induced phosphorylation of p38 MAP kinase. These results strongly suggest that Rho-kinase regulates thrombin-stimulated IL-6 synthesis via p38 MAP kinase activation in osteoblasts.
我们之前曾报道过凝血酶能刺激成骨细胞样 MC3T3-E1 细胞合成白细胞介素-6(IL-6),后者是一种强有力的破骨细胞活性物质。在本研究中,我们探讨了凝血酶刺激 IL-6 合成的机制,以及 Rho-激酶在 MC3T3-E1 细胞中的作用。凝血酶能时间依赖性地诱导 p44/p42 丝裂原激活蛋白(MAP)激酶、p38MAP 激酶、应激激活蛋白激酶/c-Jun N-末端激酶(SAPK/JNK)和肌球蛋白磷酸酶靶向亚单位-1(MYPT-1)的磷酸化,后者是 Rho-激酶的底物。虽然 SAPK/JNK 的抑制剂 SP600125 未能减少 IL-6 的合成,但 MEK 的特异性抑制剂 PD98059 和 p38 MAP 激酶的强效抑制剂 SB203580 和 BIRB0796 抑制了凝血酶诱导的 IL-6 合成。Rho-激酶的特异性抑制剂 Y27632 显著降低了凝血酶刺激的 IL-6 合成和 MYPT-1 磷酸化。另一种 Rho-激酶抑制剂法舒地尔也抑制了凝血酶刺激的 IL-6 合成。Y27632 和法舒地尔不影响凝血酶诱导的 p44/p42 MAP 激酶磷酸化。Y27632 和法舒地尔减弱了凝血酶诱导的 p38 MAP 激酶磷酸化。这些结果强烈表明,在成骨细胞中 Rho-激酶通过激活 p38 MAP 激酶来调节凝血酶刺激的 IL-6 合成。